gip/glp-1 agonist Dual receptor agonists: New advances for treating type-2 diabetes GIP and GLP‐1, the two

Any concerning symptomsincluding severe gastrointestinal distress, allergic reactions, chest pain, or neurological changeswarrant immediate medical evaluation and discontinuation of the product

however, in clinical trials for once-daily subcutaneous administration of liraglutide 3.0 mg in patients with obesity only, or with obesity and diabetes, these effects tended to be mild-to-moderate and transient

References World Obesity Federation

GIP showed a diminished effect in boosting insulin secretion in T2D patients, for reasons that are still not understood

Additionally, thyroid C-cell tumours have been observed in rodent studies of GLP-1 receptor agonists

GLP-1 receptor agonists slow down the rate at which the stomach empties its contents into the small intestine